These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31935222)

  • 1. HIV infection does not alter interferon α/β receptor 2 expression on mucosal immune cells.
    Ickler J; Francois S; Widera M; Santiago ML; Dittmer U; Sutter K
    PLoS One; 2020; 15(1):e0218905. PubMed ID: 31935222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative Differences Between the IFNα subtypes and IFNβ Influence Chronic Mucosal HIV-1 Pathogenesis.
    Guo K; Shen G; Kibbie J; Gonzalez T; Dillon SM; Smith HA; Cooper EH; Lavender K; Hasenkrug KJ; Sutter K; Dittmer U; Kroehl M; Kechris K; Wilson CC; Santiago ML
    PLoS Pathog; 2020 Oct; 16(10):e1008986. PubMed ID: 33064743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Type I Interferon Subtypes Differentially Stimulate T Cell Responses in HIV-1-Infected Individuals.
    Karakoese Z; Schwerdtfeger M; Karsten CB; Esser S; Dittmer U; Sutter K
    Front Immunol; 2022; 13():936918. PubMed ID: 35911692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Dependent Differences in HIV Inhibition by Different Interferon Alpha Subtypes While Having Overall Similar Biologic Effects.
    Schlaepfer E; Fahrny A; Gruenbach M; Kuster SP; Simon V; Schreiber G; Speck RF
    mSphere; 2019 Feb; 4(1):. PubMed ID: 30760614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.
    Harris BD; Schreiter J; Chevrier M; Jordan JL; Walter MR
    J Biol Chem; 2018 Oct; 293(41):16057-16068. PubMed ID: 30171073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ.
    Stifter SA; Matthews AY; Mangan NE; Fung KY; Drew A; Tate MD; Soares da Costa TP; Hampsey D; Mayall J; Hansbro PM; Garcia Minambres A; Eid SG; Mak J; Scoble J; Lovrecz G; deWeerd NA; Hertzog PJ
    J Biol Chem; 2018 Mar; 293(9):3168-3179. PubMed ID: 29187603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential receptor subunit affinities of type I interferons govern differential signal activation.
    Jaks E; Gavutis M; Uzé G; Martal J; Piehler J
    J Mol Biol; 2007 Feb; 366(2):525-39. PubMed ID: 17174979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFNAR2 Is Required for Anti-influenza Immunity and Alters Susceptibility to Post-influenza Bacterial Superinfections.
    Shepardson KM; Larson K; Johns LL; Stanek K; Cho H; Wellham J; Henderson H; Rynda-Apple A
    Front Immunol; 2018; 9():2589. PubMed ID: 30473701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal Ablation of Alpha/Beta Interferon (IFN-α/β) Signaling Exacerbates Central Nervous System Viral Dissemination and Impairs IFN-γ Responsiveness in Microglia/Macrophages.
    Hwang M; Bergmann CC
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32796063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms.
    Harper MS; Guo K; Gibbert K; Lee EJ; Dillon SM; Barrett BS; McCarter MD; Hasenkrug KJ; Dittmer U; Wilson CC; Santiago ML
    PLoS Pathog; 2015; 11(11):e1005254. PubMed ID: 26529416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An extracellular humanized IFNAR immunocompetent mouse model for analyses of human interferon alpha and subtypes.
    Li Y; Ashuo A; Hao M; Li Y; Ye J; Liu J; Hua T; Fang Z; Li J; Yuan Z; Chen J
    Emerg Microbes Infect; 2024 Dec; 13(1):2287681. PubMed ID: 37994664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection.
    Goritzka M; Durant LR; Pereira C; Salek-Ardakani S; Openshaw PJ; Johansson C
    J Virol; 2014 Jun; 88(11):6128-36. PubMed ID: 24648449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.
    Marijanovic Z; Ragimbeau J; van der Heyden J; Uzé G; Pellegrini S
    Biochem J; 2007 Oct; 407(1):141-51. PubMed ID: 17627610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S27 of IFNα1 Contributes to Its Low Affinity for IFNAR2 and Weak Antiviral Activity.
    Sharma N; O'Neal AJ; Gonzalez C; Wittling M; Gjinaj E; Parsons LM; Panda D; Khalenkov A; Scott D; Misra S; Rabin RL
    J Interferon Cytokine Res; 2019 May; 39(5):283-292. PubMed ID: 30920934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural integrity with functional plasticity: what type I IFN receptor polymorphisms reveal.
    de Weerd NA; Vivian JP; Lim SS; Huang SU; Hertzog PJ
    J Leukoc Biol; 2020 Sep; 108(3):909-924. PubMed ID: 33448473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-based Knockout Strategy Elucidates Components Essential for Type 1 Interferon Signaling in Human HeLa Cells.
    Urin V; Shemesh M; Schreiber G
    J Mol Biol; 2019 Aug; 431(17):3324-3338. PubMed ID: 31207241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of
    Schleicher U; Liese J; Justies N; Mischke T; Haeberlein S; Sebald H; Kalinke U; Weiss S; Bogdan C
    Front Immunol; 2018; 9():79. PubMed ID: 29459858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus Multiplicity of Infection Affects Type I Interferon Subtype Induction Profiles and Interferon-Stimulated Genes.
    Zaritsky LA; Bedsaul JR; Zoon KC
    J Virol; 2015 Nov; 89(22):11534-48. PubMed ID: 26355085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
    Ito K; Tanaka H; Ito T; Sultana TA; Kyo T; Imanaka F; Ohmoto Y; Kimura A
    Eur J Haematol; 2004 Sep; 73(3):191-205. PubMed ID: 15287917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
    Cajean-Feroldi C; Nosal F; Nardeux PC; Gallet X; Guymarho J; Baychelier F; Sempé P; Tovey MG; Escary JL; Eid P
    Biochemistry; 2004 Oct; 43(39):12498-512. PubMed ID: 15449939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.